Zacks Research Has Bullish Outlook for Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Surmodics in a note issued to investors on Wednesday, February 19th. Zacks Research analyst D. Dey now expects that the company will earn ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.87 EPS.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Several other brokerages have also recently issued reports on SRDX. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. StockNews.com assumed coverage on Surmodics in a report on Monday, February 3rd. They set a “hold” rating for the company. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $50.00.

Surmodics Price Performance

Shares of Surmodics stock opened at $34.85 on Monday. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The stock has a market cap of $498.36 million, a PE ratio of -34.50 and a beta of 1.20. The company’s 50-day moving average price is $37.02 and its two-hundred day moving average price is $38.34.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Olympiad Research LP purchased a new position in Surmodics during the 3rd quarter valued at about $1,884,000. Principal Financial Group Inc. purchased a new stake in shares of Surmodics in the third quarter worth approximately $1,190,000. Wolverine Asset Management LLC boosted its holdings in shares of Surmodics by 6.9% during the third quarter. Wolverine Asset Management LLC now owns 27,766 shares of the company’s stock worth $1,077,000 after purchasing an additional 1,800 shares during the period. Quest Partners LLC grew its position in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after purchasing an additional 1,071 shares in the last quarter. Finally, Phocas Financial Corp. acquired a new position in Surmodics in the 3rd quarter valued at approximately $3,430,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Timothy J. Arens sold 7,009 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares of the company’s stock, valued at $2,774,604. This trade represents a 9.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 8.90% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).